A Case of Paraneoplastic Myoclonus Attributed to Non-Small Cell Lung
                        Cancer

Nichols, James Hastings; Lee, Brett J.; Chung, Kathryn A.

doi:10.5334/tohm.42

Tremor and Other Hyperkinetic Movements

2020

DOI: 10.5334/tohm.42

|View full text |Cite

A Case of Paraneoplastic Myoclonus Attributed to Non-Small Cell Lung Cancer

James Hastings Nichols

Brett J. Lee

Kathryn A. Chung

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

肺癌による傍腫瘍性神経症候群としての嚥下機能障害がオシメルチニブ投与により改善した1例

Hiruta,

Suzuki,

Matsuda

et al. 2023

JJLC

View full text Add to dashboard Cite

━━ Background. Lung cancer is the most common cause of paraneoplastic neurological syndrome (PNS), but there are few reports of its occurrence in cases of non-small cell lung cancer. Case. A 75-year-old woman visited our hospital with a chief complaint of dysphagia, but no organic or neurological abnormalities that could cause dysphagia were found. Chest computed tomography (CT) detected a lung nodule 1.5 cm in size in the right middle lobe and another 1.9 cm in size in the left lower lobe. Based on these CT findings, PNS due to lung cancer was suspected. Positron emission tomography (PET)/CT showed the uptake of fluorodeoxyglucose (FDG) with a maximum standardized uptake value of 5.0 only in the right middle lobe lesion, suggesting right middle lobe lung cancer (cT1bN0M0, stage IA2). Based on these findings, right middle lobectomy and lymph node dissection were performed. Pathologically, the patient was diagnosed with EGFR mutation (Exon21 L858R)-positive pulmonary adenocarcinoma (pT2aN2M0, stage IIIA). At that time, the other lesion in the left lower lobe was clinically judged to be intrapulmonary metastasis from lung cancer in the right lung, so the patient was administered osimertinib (80 mg/day). Dysphagia improved seven days after administration, and there has been no recurrence for 10 months. Conclusion. Molecular-targeted therapy for a tumor can improve PNS in EGFR mutation-positive lung adenocarcinoma.

show abstract

肺癌による傍腫瘍性神経症候群としての嚥下機能障害がオシメルチニブ投与により改善した1例

Hiruta,

Suzuki,

Matsuda

et al. 2023

JJLC

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Case of Paraneoplastic Myoclonus Attributed to Non-Small Cell Lung Cancer

Cited by 1 publication

References 8 publications

肺癌による傍腫瘍性神経症候群としての嚥下機能障害がオシメルチニブ投与により改善した1例

肺癌による傍腫瘍性神経症候群としての嚥下機能障害がオシメルチニブ投与により改善した1例

Contact Info

Product

Resources

About